Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Noninvasive assessment of cell proliferation in ovarian cancer using [18F] 3'deoxy-3-fluorothymidine positron emission tomography/computed tomography imaging.

Richard SD, Bencherif B, Edwards RP, Elishaev E, Krivak TC, Mountz JM, DeLoia JA.

Nucl Med Biol. 2011 May;38(4):485-91. doi: 10.1016/j.nucmedbio.2010.12.003. Epub 2011 Mar 3.

PMID:
21531285
2.

Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation.

Barwick T, Bencherif B, Mountz JM, Avril N.

Nucl Med Commun. 2009 Dec;30(12):908-17. doi: 10.1097/MNM.0b013e32832ee93b. Review.

PMID:
19794320
3.

FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3'-deoxy-3'-[18F]fluorothymidine.

Salskov A, Tammisetti VS, Grierson J, Vesselle H.

Semin Nucl Med. 2007 Nov;37(6):429-39. Review. Erratum in: Semin Nucl Med. 2008 Mar;38(2):148.

PMID:
17920350
4.

[Is 3'-deoxy-3'- [18F] fluorothymidine ([18F]-FLT) the next tracer for routine clinical PET after R [18F]-FDG?].

Couturier O, Leost F, Campone M, Carlier T, Chatal JF, Hustinx R.

Bull Cancer. 2005 Sep;92(9):789-98. Review. French.

PMID:
16203269
5.

Imaging of cell proliferation: status and prospects.

Bading JR, Shields AF.

J Nucl Med. 2008 Jun;49 Suppl 2:64S-80S. doi: 10.2967/jnumed.107.046391. Review.

6.

Molecular imaging metrics to evaluate response to preclinical therapeutic regimens.

Smith RA, Guleryuz S, Manning HC.

Front Biosci (Landmark Ed). 2011 Jan 1;16:393-410. Review.

7.

Ovarian cancer: linking genomics to new target discovery and molecular markers--the way ahead.

Hennessy BT, Murph M, Nanjundan M, Carey M, Auersperg N, Almeida J, Coombes KR, Liu J, Lu Y, Gray JW, Mills GB.

Adv Exp Med Biol. 2008;617:23-40. doi: 10.1007/978-0-387-69080-3_3. Review. No abstract available.

Items per page

Supplemental Content

Write to the Help Desk